

Estimate change	↓
TP change	↓
Rating change	↔

CMP: INR4,537 TP: INR5,150 (+14%) Buy

A weak quarter, but reset in progress

All eyes now on new management for turnaround

- LTIMindtree (LTIM) reported 4QFY25 revenue of USD1.1b, down 0.6% QoQ CC and below our estimate of flat QoQ CC. FY25 revenue stood at USD4.5b, up 5.0% YoY CC. 4Q EBIT margin at 13.8% was in line with our estimate of 13.8%. 4Q PAT stood at INR11.2b, up 3.9% QoQ/2.5% YoY and slightly below our estimate of INR12b. FY25 revenue grew 7.0% YoY, EBIT declined 1.2%, and PAT remained largely flat in INR terms. In 1QFY26, we expect revenue/EBIT/PAT to grow 8.3%/15.2%/7.3% YoY. We value LTIM at 26x FY27E EPS and our revised TP of INR5,150 implies a 14% upside potential.

Our view: Awaiting a concrete turnaround plan for growth and margins

- **Microsoft productivity gain episode now done, but macro uncertainty could limit growth upside in FY26:** There is no overhang of the Microsoft productivity pass-through beyond 4Q; however, we believe FY26 could be a year of mediocre growth. We expect LTIM to report ~5% CC growth in FY26E.
- **A new cost-saving initiative, however we await concrete margin expansion direction:** LTIM has launched its “Fit for Future” initiative to drive cost efficiency and improve profitability, starting in 1QFY26. This includes reassessing direct and indirect costs, optimizing delivery and sales structures, and continuing pyramid correction efforts. Though these steps align well with client demand for cost savings and modernization, management has not provided a tighter guidance range or timeline, which makes the margin expansion trajectory a tad vague, in our view.
- **Long way to go; cut target multiple:** We believe the new management has their task cut out, and the added macro uncertainty pushes back the prospect of a double-digit growth **rate** as well as normalized EBIT margins beyond FY27. We cut our target multiple by ~10%. A successful turnaround could lead to re-rating, and the current price offers valuation comfort. We thus maintain a BUY rating.

Miss on revenues and in-line margins (miss on consensus); deal TCV down ~5% QoQ

- Revenue stood at USD1.1b, down 0.6% QoQ CC and below our estimate of flat QoQ CC. Reported USD revenue was down 0.7% QoQ/up 5.8% YoY. For FY25, revenue stood at USD4.5b, up 5.0% YoY CC.
- Manufacturing & Resources grew 2.3% QoQ and BFSI was up 1.2% QoQ. Hi-Tech was down 1.5% QoQ, while Retail/Life Sciences declined 2.4%/14.0% QoQ.
- EBIT margin at 13.8% was in line with our estimate of 13.8%. For FY25, EBIT margin stood at 14.5% vs. 15.7% in FY24.
- Employee metrics: Software headcount declined by ~2,560 (-3.1% QoQ), utilization inched up 40bp QoQ to 85.8%, and attrition was up 10bp QoQ at 14.4%.

Bloomberg	LTIM IN
Equity Shares (m)	296
M.Cap.(INRb)/(USDb)	1344.2 / 15.7
52-Week Range (INR)	6768 / 3802
1, 6, 12 Rel. Per (%)	-4/-23/-13
12M Avg Val (INR M)	2562

Financials & Valuations (INR b)

Y/E Mar	FY25	FY26E	FY27E
Sales	380.1	405.9	440.5
EBIT Margin (%)	14.5	15.0	15.6
PAT	46.0	51.1	57.3
EPS (INR)	155.3	172.4	193.6
EPS Gr. (%)	0.3	11.0	12.3
BV/Sh. (INR)	766.2	866.5	979.1

Ratios

RoE (%)	23.3	21.1	21.0
RoCE (%)	19.0	17.4	17.5
Payout (%)	41.8	41.8	41.8

Valuations

P/E (x)	29.2	26.3	23.4
P/BV (x)	5.9	5.2	4.6
EV/EBITDA (x)	19.0	16.8	15.0
Div Yield (%)	1.4	1.6	1.8

Shareholding pattern (%)

As On	Mar-25	Dec-24	Mar-24
Promoter	68.6	68.6	68.6
DII	15.6	15.0	13.6
FII	7.0	7.5	7.9
Others	8.8	9.0	10.0

FII Includes depository receipts



- PAT came in at INR11.2b, up 3.9% QoQ/2.5% YoY and slightly below our estimate of INR12b. FY25 PAT stood at INR46b, flat YoY.
- Order inflows stood at USD1.6b, down ~4.7% QoQ. FY25 order book stood at USD6b.
- The company declared a final dividend of INR45/share for FY25.

Key highlights from the management commentary

- FY25 was a year of consolidation; discretionary spending remained muted in 4Q.
- 2H momentum slowed due to ongoing macro uncertainty, which persisted in 4Q.
- Strategic initiatives for FY26: 1) Sales Transformation – Realignment of service lines and sales structure to target a broader portion of client spend via the AI economy. 2) Robust GTM – Focus on multi-service, multi-delivery, and multi-geography models. 3) Fit for Future – Drive agility and profitability by reassessing direct/indirect costs, improving efficiency across sales and delivery. Margin improvement is expected to start in 1QFY26.
- Clients were largely in "wait-and-watch" mode during 4Q, but they are opening up now for conversations.
- LTIM is adjusting its portfolio from a higher discretionary mix to longer-term efficiency programs. Some closed deals failed to ramp up as planned; certain 4Q deals got delayed.
- **Technology, Media, and Communications:** Productivity gains delivered to the top client in 3Q and 4Q. No pricing reset has happened and no future impact is expected on pass-backs.
- **Consumer:** There were some client-specific issues in the Travel, Transport & Hospitality portfolios. Those clients are now planning new initiatives. No material impact observed from tariff-related changes.
- Headcount was ramped up in 2Q/3Q in anticipation of 4Q deal execution, which did not materialize, leading to a drop in headcount.

Valuation and view

- We maintain our BUY rating on LTIM, supported by its capabilities in data engineering and ERP modernization. The current stock price also offers attractive valuation comfort. While our FY26 estimates remain largely unchanged, we lower our FY27 EPS estimate by ~5% to account for the current macroeconomic headwinds. We now value LTIM at 26x FY27E EPS (earlier 30x), leading to a revised TP of INR 5,150, implying a 14% upside from the current level.

Exhibit 1: Deal win at USD1.6b, down ~5% QoQ; book-to-bill at 1.4x

Exhibit 2: Headcount normalization after anticipated 4Q deal execution did not materialize

Exhibit 3: North America and Europe declined QoQ

Geographies (QoQ %)	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25
North America	3.8	7.0	6.1	1.6	0.5	1.8	2.0	-0.2	0.2	4.3	2.6	0.7	-0.9
Europe	3.5	-6.7	-0.4	4.5	4.4	-1.2	2.3	-4.5	-0.6	1.1	2.8	-3.1	-2.1
RoW	-2.2	-0.2	0.3	4.9	0.2	-7.8	-1.9	14.1	-10.6	-7.2	3.8	9.7	2.8

Source: MOFSL, Company

Exhibit 4: Healthcare and Retail performed poorly in 4Q while BFSI and Manufacturing were defensive

Verticals (QoQ %)	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25
BFSI	4.0	5.7	4.6	5.8	2.7	-1.2	-1.1	-1.7	-2.7	2.8	3.9	3.3	1.2
Manufacturing	-2.2	-2.9	3.7	10.6	1.0	-1.0	5.1	14.3	-9.6	2.0	0.6	7.8	2.4
CPG, Retail & Pharma	3.5	3.7	2.3	1.1	2.4	-1.8	2.9	-3.2	1.4	-1.6	2.8	-0.3	-2.1
Technology, Media & Communications	4.1	5.3	3.9	-4.5	-1.5	3.2	2.0	-3.0	4.7	8.0	2.0	-5.7	-1.9
Healthcare	1.3	6.9	7.5	-5.1	-2.2	5.0	3.2	0.8	4.8	-7.9	6.1	-0.5	-13.3

Source: MOFSL, Company

Quarterly Performance

Y/E March	FY24				FY25				FY24	FY25	Est. 4QFY25	Var. (% / bp)
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q				
Revenue (USD m)	1,059	1,076	1,084	1,069	1,096	1,127	1,139	1,131	4,287	4,493	1,136	(0.5)
QoQ (%)	0.1	1.6	0.8	-1.3	2.5	2.8	1.1	-0.7	4.4	4.8	-0.2	(46)
Revenue (INR B)	87	89	90	89	91	94	97	98	355	380	99	(0.8)
YoY (%)	13.8	8.2	4.6	2.3	5.1	5.9	7.1	9.9	7.0	7.0	10.8	(89)
GPM (%)	31.6	31.4	29.9	29.8	30.3	30.8	28.8	27.9	30.7	29.4	29.0	(109)
SGA (%)	12.8	13.1	12.3	12.5	12.7	12.8	12.3	11.6	12.7	12.3	12.5	(92)
EBITDA	16	16	16	15	16	17	16	16	64	65	16	(1.8)
EBITDA Margin (%)	18.8	18.3	17.6	17.3	17.6	18.0	16.5	16.3	18.0	17.1	16.5	(17)
EBIT	15	14	14	13	14	15	13	13	56	55	14	(1.0)
EBIT Margin (%)	16.7	16.0	15.4	14.7	15.0	15.5	13.8	13.8	15.7	14.5	13.8	(3)
Other income	0.9	1.0	1.6	1.4	1.5	2.3	1.4	1.8	5	7	2	4
ETR (%)	25.0	23.5	24.3	24.0	25.6	25.8	26.2	26.2	24.2	25.9	25.0	
Adj PAT	12	12	12	11	11	13	11	11	46	46	12	(2.1)
QoQ (%)	3.4	0.9	0.6	-5.9	3.1	10.3	-13.2	3.9			6.1	
YoY (%)	4.1	-2.2	8.2	-1.2	-1.5	7.7	-7.1	2.5	2.1	0.4	4.7	
EPS (INR)	38.9	39.2	39.4	37.1	38.2	42.2	36.6	38.0	154.5	155.0	38.9	(2.2)

Key Perfor. Indicators

Y/E March	FY24				FY25				FY24	FY25
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q		
Revenue (QoQ CC %)	0.1	1.7	0.7	-1.3	2.6	2.3	1.8	-0.6		
Margins (%)										
Gross Margin	31.6	31.4	29.9	29.8	30.3	30.8	28.8	27.9	30.7	29.4
EBIT Margin	16.7	16.0	15.4	14.7	15.0	15.5	13.8	13.8	15.7	14.5
Net Margin	13.2	13.1	13.0	12.4	12.4	13.3	11.2	11.5	12.9	12.1
Operating metrics										
Headcount	82,738	83,532	82,471	81,650	81,934	84,438	86,800	84,307	81,650	84,307
Attrition (%)	17.8	15.2	14.2	14.4	14.4	14.5	14.3	14.4	14.4	14.4
Utilization (excl. trainees)	84.8	86.6	87.4	86.9	88.3	87.7	85.4	85.8	86.4	86.8
Key Verticals (QoQ %)										
BFSI	-1.2	-1.1	-1.7	-2.7	2.8	3.9	3.3	1.2	2.2	4.5
CMT	3.2	2.0	-3.0	4.7	8.0	2.0	-5.7	-1.9	1.7	8.5
MFG	-1.0	5.1	14.3	-9.6	2.0	0.6	7.8	2.4	14.6	7.2
Healthcare	5.0	3.2	0.8	4.8	-7.9	6.1	-0.5	-13.3	6.5	-2.8
CPG, Retail and Pharma	-1.8	2.9	-3.2	1.4	-1.6	2.8	-0.3	-2.1	1.9	-0.1
Key Geographies (QoQ %)										
North America	1.8	2.0	-0.2	0.2	4.3	2.6	0.7	-0.9	5.9	7.0
Europe	-1.2	2.3	-4.5	-0.6	1.1	2.8	-3.1	-2.1	3.4	-1.2



Key highlights from the management commentary

Demand and industry outlook

- FY25 was a year of consolidation; discretionary spending remained muted in 4Q.
- 2H momentum slowed due to ongoing macro uncertainty, which persisted in 4Q.
- Strategic initiatives for FY26: 1) **Sales Transformation** – Realignment of service lines and sales structure to target a broader portion of client spend via the AI economy. 2) **Robust GTM** – Focus on multi-service, multi-delivery, and multi-geography models. 3) **Fit for Future** – Drive agility and profitability by reassessing direct/indirect costs, improving efficiency across sales and delivery. Margin improvement expected to start in 1QFY26.
- LTIM sees the current tech transformation phase (especially AI) as an opportunity. Demand in the current environment is concentrated around cost-saving, vendor consolidation, and tech modernization.
- Management is confident about a return to growth in 1QFY26.
- Order inflow was USD1.6b in 4QFY25, down ~4.7% QoQ. FY25 total TCV was USD6b. LTIM is adjusting its portfolio from a higher discretionary mix to longer-term efficiency programs. Some closed deals failed to ramp up as planned; certain 4Q deals got delayed.
- Engaged in a couple of large deal conversations with retail clients.
- Management expects order book in FY26 to be better than FY25, with deal ramp-ups starting from 1QFY26.
- Clients were largely in "wait-and-watch" mode during 4Q, but they are opening up now for conversations.
- **Manufacturing & Resources:** Growth supported by prior large deal wins. Deals are mostly signed for vendor consolidation, managed services, and ERP transformation. The outlook is steady and growth-oriented.
- **Technology, Media, and Communications:** Productivity gains delivered to the top client in 3Q and 4Q. No pricing reset has happened and no future impact is expected on pass-backs.
- **Consumer:** There were some client-specific issues in the Travel, Transport & Hospitality portfolios. Those clients are now planning new initiatives. No material impact observed from tariff-related changes.
- **Healthcare, Life Sciences & Public Services:** Segment declined 13% QoQ — the smallest vertical in the portfolio. No specific client issues. Business here is largely project-based, especially in healthcare and public services.
- Headcount was ramped up in 2Q/3Q in anticipation of 4Q deal execution, which did not materialize, leading to a drop in headcount.
- Onboarded 4,700 freshers in FY25 as part of pyramid correction strategy. AI-driven productivity to drive non-linear growth.
- Declared a final dividend of INR45/share for FY25.

Margin performance

- 4Q EBIT margin was 13.8%, in line with our estimates. FY25 EBIT margin came in at 14.5%, down from 15.7% in FY24.
- Margin pressure in 3Q and 4Q was due to wage hikes.
- Focus areas for margin improvement would be pyramid correction and an improved span of control.

Exhibit 5: Top client buckets dropped sequentially

Clients	Contribution to Revenue (%)	QoQ growth (%)	YoY growth (%)
Top five clients	27.7	-1.4	3.5
Top 10 clients	34.3	-1.3	2.2
Top 20 clients	44.8	-2.2	3.2

Source: MOFSL, Company

Exhibit 6: Changes to our estimates

	Revised		Earlier		Change	
	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
INR/USD	86.0	86.0	86.0	86.0	0.0%	0.0%
USD Revenue (m)	4,723	5,125	4,810	5,297	-1.8%	-3.3%
Growth (%)	5.1	8.5	6.9	10.1	-180bps	-160bps
EBIT margin (%)	15.0	15.6	15.0	15.9	0bps	-40bps
PAT (INR m)	51,074	57,340	52,016	60,502	-1.8%	-5.2%
EPS	172.4	193.6	175.5	204.2	-1.8%	-5.2%


Source: MOFSL, Company

Valuation and view

- **We maintain our BUY rating on LTIM**, supported by its capabilities in data engineering and ERP modernization. The current stock price also offers attractive valuation comfort. While our FY26 estimates remain largely unchanged, we lower our FY27 EPS estimate by ~5% to account for the current macroeconomic headwinds. We now value LTIM at 26x FY27E EPS, leading to a revised TP of INR5,150, implying a 14% upside from the current levels.


Story in charts

Exhibit 1: Revenue declined QoQ




Source: Company, MOFSL

Exhibit 2: EBIT margins were flat QoQ




Source: Company, MOFSL

Exhibit 3: Attrition remained stable




Source: Company, MOFSL

Exhibit 4: BFSI continued its growth momentum despite macro headwinds




Source: Company, MOFSL

Exhibit 5: Utilization inched up by 40bps in 4Q



Source: Company, MOFSL

Exhibit 6: Effort mix remained unchanged



Source: Company, MOFSL

Operating metrics

Exhibit 1: Operating metrics

	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25
Revenue by verticals (%)									
BFSI	38.0	37.5	36.5	35.6	35.1	35.2	35.6	36.4	37.1
Manufacturing	17.5	17.3	17.9	20.3	18.6	18.5	18.1	19.3	19.9
CPG, retail & pharma	15.4	15.1	15.3	14.7	15.1	14.5	14.5	14.3	14.1
High tech, media & entertainment	23.0	23.7	23.8	22.9	24.3	25.6	25.4	23.7	23.4
Healthcare, Life, Public Science	6.1	6.4	6.5	6.5	6.9	6.2	6.4	6.3	5.5
Revenue by geography (%)									
North America	71.9	73.1	73.4	72.7	73.8	75.1	75.0	74.7	74.5
Europe	15.4	15.2	15.3	14.5	14.6	14.4	14.4	13.8	13.6
ROW	12.7	11.7	11.3	12.8	11.6	10.5	10.6	11.5	11.9
Client metrics (% of revenues)									
Top 5 client	25.4	26.7	26.8	27.5	28.3	28.8	28.4	27.9	27.7
Top 10 client	32.9	34.1	34.3	35.3	35.5	35.7	35.0	34.5	34.3
Top 20 client	44.0	44.9	45.2	45.9	45.9	46.2	45.8	45.5	44.8
Top 40 client	56.8	57.2	57.6	58.5	58.0	58.9	58.2	58.1	57.2
Non-Top 20 clients	56.0	55.1	54.8	54.1	54.1	53.8	54.2	54.5	55.2
Number of active clients	728	723	737	739	738	748	742	742	741
New clients added in the period	31	19	30	23	30	27	22	23	26
Million \$ clients									
5 Million \$ clients	146	148	146	149	153	148	154	152	154
10 Million \$ clients	81	88	90	89	91	87	88	90	89
20 Million \$ clients	38	40	41	40	40	43	42	39	40
50 Million \$ clients	13	13	14	12	13	12	12	13	14
100 Million \$ clients	2	2	2	2	2	2	2	2	2
Employee metrics									
Development	80,283	77,555	78,276	77,203	76,460	76,837	79,374	81,641	79,081
Sales and support	4,263	5,183	5,256	5,268	5,190	5,097	5,064	5,159	5,226
Total employees	84,546	82,738	83,532	82,471	81,650	81,934	84,438	86,800	84,307
Efforts mix									
Onsite	14.9	14.8	14.8	15.0	15.1	15.4	15.5	15.4	15.1
Offshore	85.1	85.2	85.2	85.0	84.9	84.6	84.5	84.6	84.9
Utilization measures									
Excluding trainees	81.7	84.8	86.6	87.4	86.9	88.3	87.7	85.4	85.8
Attrition LTM (%)	20.2	17.8	15.2	14.2	14.4	14.4	14.5	14.3	14.4

Source: Company, MOFSL

Financials and valuations

Income Statement							(INR m)	
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Sales	2,69,413	2,86,287	2,61,086	3,31,830	3,55,170	3,80,081	4,05,917	4,40,479
Change (%)	12.2	6.3	(8.8)	27.1	7.0	7.0	6.8	8.5
Cost of Services	1,77,967	1,95,985	1,78,271	2,32,037	2,46,214	2,68,217	2,86,671	3,11,609
Gross Profit	91,446	90,302	82,815	99,793	1,08,956	1,11,864	1,19,246	1,28,870
SG&A Expenses	36,068	26,759	30,330	37,915	45,082	46,915	47,493	50,655
EBITDA	55,378	63,543	52,485	61,878	63,874	64,949	71,752	78,215
% of Net Sales	20.6	22.2	20.1	18.6	18.0	17.1	17.7	17.8
Depreciation	8,239	8,520	5,971	7,227	8,189	9,915	10,960	9,691
EBIT	47,139	55,023	46,514	54,651	55,685	55,034	60,792	68,525
% of Net Sales	17.5	19.2	17.8	16.5	15.7	14.5	15.0	15.6
Other Income	1,796	3,410	6,426	4,065	4,802	7,108	7,307	7,929
PBT	48,934	58,434	52,940	58,716	60,487	62,142	68,099	76,453
Tax	8,780	14,262	13,439	13,812	14,641	16,122	17,025	19,113
Rate (%)	17.9	24.4	25.4	23.5	24.2	25.9	25.0	25.0
Minority Interest	0	0	0	11	25	27	0	0
Extraordinary	0	-571	0	800	0	0	0	0
Adjusted PAT	40,154	44,172	39,501	44,904	45,846	46,020	51,074	57,340
Change (%)	-3	10	-11	14	2	0	11	12

Balance Sheet							(INR m)	
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Share Capital	174	175	296	296	296	296	296	296
Reserves	53,866	72,859	1,42,576	1,65,625	1,99,876	2,26,687	2,56,400	2,89,757
Net Worth	54,040	73,034	1,42,872	1,65,921	2,00,172	2,26,983	2,56,696	2,90,053
Minority Interest	11	37	57	71	92	132	132	132
Other liabilities	10,886	7,697	11,972	14,143	17,934	19,526	19,511	19,553
Capital Employed	64,937	80,768	1,54,901	1,80,135	2,18,198	2,46,641	2,76,338	3,09,739
Net Block	12,104	10,481	13,772	17,823	21,224	25,406	22,446	20,756
Intangibles	7,684	9,241	14,861	15,452	15,078	14,212	14,212	14,212
Other LT Assets	5,170	6,056	27,805	29,789	50,798	57,303	49,675	52,198
Curr. Assets	63,290	81,313	1,49,386	1,71,897	1,88,530	2,09,379	2,42,427	2,78,555
Current Investments	22,186	36,282	57,882	53,349	77,494	88,999	1,08,999	1,28,999
Debtors	27,541	26,906	56,271	72,284	70,387	76,882	71,174	77,235
Cash & Bank Balance	5,252	7,594	14,462	23,389	18,200	20,623	31,104	38,752
Other Current Assets	8,311	10,531	20,771	22,875	22,449	22,875	31,150	33,570
Current Liab. & Prov	23,311	26,323	50,923	54,826	57,432	59,659	52,422	55,982
Trade payables	7,269	8,277	13,250	12,938	14,939	15,499	10,148	11,012
Other liabilities	13,454	14,504	31,381	33,754	34,007	34,469	32,584	35,279
Provisions	2,588	3,542	6,292	8,134	8,486	9,691	9,691	9,691
Net Current Assets	39,979	54,990	98,463	1,17,071	1,31,098	1,49,720	1,90,005	2,22,573
Application of Funds	64,937	80,768	1,54,901	1,80,135	2,18,198	2,46,641	2,76,338	3,09,739

Pro Forma P&L statement for the combined entity (LTIM) from FY20 to FY21

* Standalone (LTI) Balance Sheet from FY20 to FY21

Financials and valuations

Ratios

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
EPS	89.4	98.9	133.5	151.8	154.8	155.3	172.4	193.6
Cash EPS	107.8	117.8	153.7	173.5	182.5	188.8	209.4	226.3
Book Value	120.3	161.5	483.0	560.9	676.0	766.2	866.5	979.1
DPS	22.7	37.6	63.9	60.0	65.0	65.0	72.1	81.0
Payout (%)	25.4	38.0	47.9	39.5	42.0	41.8	41.8	41.8
Valuation (x)								
P/E ratio	50.7	45.8	34.0	29.9	29.3	29.2	26.3	23.4
Cash P/E ratio	42.1	38.5	29.5	26.1	24.9	24.0	21.7	20.1
EV/EBITDA ratio	36.3	31.6	24.2	20.4	19.5	19.0	16.8	15.0
EV/Sales ratio	7.5	7.0	4.9	3.8	3.5	3.2	3.0	2.7
Price/Book Value ratio	37.7	28.1	9.4	8.1	6.7	5.9	5.2	4.6
Dividend Yield (%)	0.5	0.8	1.4	1.3	1.4	1.4	1.6	1.8
Profitability Ratios (%)								
RoE	78.0	70.4	36.6	26.1	24.4	23.3	21.1	21.0
RoCE	67.2	57.1	29.5	24.9	21.2	19.0	17.4	17.5
Turnover Ratios								
Debtors (Days)	37.31	34.30	79	80	72	74	64	64
Fixed Asset Turnover (x)	22.3	27.3	19.0	18.6	16.7	15.0	18.1	21.2

Cash Flow Statement

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E
CF from Operations	44,695	48,591	50,720	50,261	62,034	67,030
Cash for Working Capital	-12,188	-17,645	5,975	-4,803	-2,192	-7,400
Net Operating CF	32,507	30,946	56,695	45,458	59,842	59,630
Net Purchase of FA	-10,529	-9,346	-8,330	-9,336	-8,000	-8,000
Free Cash Flow	21,978	21,600	48,365	36,122	51,842	51,630
Net Purchase of Invest.	-5,924	6,037	-30,791	-8,046	-20,000	-20,000
Net Cash from Invest.	-16,453	-3,309	-39,121	-17,382	-28,000	-28,000
Proc. from equity issues	2	12	0	0	0	0
Proceeds from LTB/STB	-3,529	-3,702	-4,947	-6,498	0	0
Dividend Payments	-13,277	-15,627	-17,753	-19,246	-21,362	-23,982
Cash Flow from Fin.	-16,804	-19,317	-22,700	-25,744	-21,362	-23,982
Exchange difference	21	607	-63	91	0	0
Net Cash Flow	-729	8,927	-5,189	2,423	10,481	7,648
Opening Cash Bal.	15,191	14,462	23,389	18,200	20,623	31,104
Add: Net Cash	-729	8,927	-5,189	2,423	10,481	7,648
Closing Cash Bal.	14,462	23,389	18,200	20,623	31,104	38,752

E: MOFSL estimates

Investment in securities market is subject to market risks. Read all the related documents carefully before investing

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).

6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

financial interest in the subject company

actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

received compensation/other benefits from the subject company in the past 12 months

any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263;

www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.